Key Highlights

  • Consensus EPS of 2.55 sits within fiscal fourth-quarter non-GAAP EPS guidance of 2.47 to 2.63, against third-quarter 2.32.
  • Consensus revenue of USD 1.36 billion sits within fiscal fourth-quarter guidance of USD 1.33 billion to USD 1.38 billion.
  • Management guided fiscal fourth-quarter non-GAAP operating margin of 6.1% to 6.5%, against 6.3% in the third quarter.
  • Third-quarter revenue was USD 1,304,778 thousand against USD 1,018,308 thousand, with non-GAAP EPS of 2.32 and diluted EPS of 1.58.

Plexus (NASDAQ:PLXS) reports fourth-quarter results on Wednesday, Oct. 28, after the market closes. Consensus stands at EPS of 2.55 on revenue of USD 1.36 billion, and the company has a market capitalization of USD 5.93 billion.

Plexus provides electronics manufacturing and engineering services to customers in industrial, healthcare and life sciences, and aerospace and defense markets. Fiscal third-quarter revenue was USD 1,304,778 thousand against USD 1,018,308 thousand, and net income was USD 42,993 thousand against USD 45,116 thousand.

Estimates Against Fiscal Fourth-Quarter Guidance

The EPS estimate of 2.55 is within fiscal fourth-quarter non-GAAP EPS guidance of 2.47 to 2.63, and above third-quarter non-GAAP EPS of 2.32, which exceeded guidance of 2.02 to 2.18. The estimates table does not state its EPS basis, and third-quarter diluted EPS was 1.58.

The revenue estimate of USD 1.36 billion is within fiscal fourth-quarter revenue guidance of USD 1.33 billion to USD 1.38 billion. Management also guided non-GAAP operating margin of 6.1% to 6.5% and nonoperating expense of approximately USD 6.3 million.

What Management Guided and What It Left Open

For fiscal 2026, management guided revenue growth of more than 20%, non-GAAP operating margin above 6.0% and capital expenditures of USD 100 million to USD 120 million. It said fiscal 2027 revenue growth has potential to exceed its long-term goal of 9% to 12%.

Management left open free cash flow, saying it now expects a usage for fiscal 2026 as working capital investments support revenue growth, and a return to generation exceeding USD 100 million in fiscal 2027. It also noted a tightening supply chain.

Sector Revenue, Wins and Funnel Detail

Industrial revenue was USD 589 million, up 23% sequentially, healthcare and life sciences revenue was USD 483 million, up 2%, and aerospace and defense revenue was USD 233 million, up 10%. Total revenue was up 12% sequentially and 28% year over year.

Manufacturing wins were 31 programs representing USD 255 million in annualized revenue when fully ramped. Aerospace and defense wins were USD 135 million for the quarter, and the qualified opportunity funnel was USD 4.5 billion.

Income Statement Lines, Cash and Capital

Cost of sales was USD 1,173,399 thousand against USD 915,020 thousand, and gross profit was USD 131,379 thousand against USD 103,288 thousand. Operating income was USD 61,260 thousand against USD 53,608 thousand, and interest expense was USD 4,089 thousand against USD 2,501 thousand.

Income before income taxes was USD 56,449 thousand against USD 49,836 thousand. Return on invested capital was 14.9% and the cash cycle was 62 days. Cash and cash equivalents were USD 314,053 thousand, and USD 20.6 million went to share repurchases. The estimates table lists a market capitalization of USD 5.93 billion.

Items to Track in the Report

Reported EPS against 2.55 and revenue against USD 1.36 billion are the headline comparisons. Other markers are sector revenue, program wins and the fiscal 2027 outlook.